Safety and efficacy of 177lu-PSMA-617 radioligand therapy in patients with mCRPC: A multicenter study.

被引:2
|
作者
Rahbar, Kambiz
Ahmadzadehfar, Hojjat
Kratochwil, Clemens
Baum, Richard P.
Schmidt, Matthias
Pfestroff, Andreas
Prasad, Vikas
Heinzel, Aelxander
Ruf, Juri
Eveslage, Maria
Boegemann, Martin
Fendler, Wolfgang
Krause, Bernd J.
机构
[1] Univ Hosp Muenster, Dept Nucl Med, Munster, Germany
[2] Univ Hosp Bonn, Dept Nucl Med, Bonn, Germany
[3] Heidelberg Univ, Dept Nucl Med, Heidelberg, Germany
[4] Zentralklin Bad Berka, Bad Berka, Germany
[5] Univ Cologne, Dept Nucl Med, Cologne, Germany
[6] Univ Marburg, Dept Nucl Med, Marburg, Germany
[7] Charite, Dept Nucl Med, Med Ctr, Berlin, Germany
[8] Univ Aachen, Dept Nucl Med, Aachen, Germany
[9] Univ Freiburg, Dept Nucl Med, Freiburg, Germany
[10] Univ Hosp Muenster, IBKF, Munster, Germany
[11] Univ Munster, Med Ctr, Munster, Germany
[12] Univ Munich LMU, Dept Nucl Med, Munich, Germany
[13] Univ Rostock, Dept Nucl Med, Rostock, Germany
关键词
D O I
10.1200/JCO.2017.35.6_suppl.155
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
155
引用
收藏
页数:1
相关论文
共 50 条
  • [21] Therapeutic response and safety of radioligand therapy with 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer patients
    Ashfaq, Wardah
    Rehman, Khurram
    Shahid, Abubaker
    Younis, Muhammad Numair
    [J]. MEDICAL ONCOLOGY, 2024, 41 (09)
  • [22] 177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer
    von Eyben, Finn E.
    Kiljunen, Timo
    Joensuu, Timo
    Kairemo, Kalevi
    Uprimny, Christian
    Virgolini, Irene
    [J]. ONCOTARGET, 2017, 8 (39) : 66112 - 66116
  • [23] Management of Dry Eye Toxicity After Treatment With 177Lu-PSMA-617 Radioligand Therapy
    Pepin, Abigail
    Lee, Vivian
    O'Brien, Sophia
    Mulugeta, Philipose
    Taunk, Neil K.
    [J]. PRACTICAL RADIATION ONCOLOGY, 2024, 14 (04) : 301 - 304
  • [24] Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer
    Fendler, Wolfgang P.
    Stuparu, Andreea D.
    Evans-Axelsson, Susan
    Luckerath, Katharina
    Wei, Liu
    Kim, Woosuk
    Poddar, Soumya
    Said, Jonathan
    Radu, Caius G.
    Eiber, Matthias
    Czernin, Johannes
    Slavik, Roger
    Herrmann, Ken
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (11) : 1786 - 1792
  • [25] Radioligand Therapy with 7.4 GBq 177-Lu-PSMA-617 in patients with mCRPC in a 6 weekly interval
    Braeuer, A.
    Seifert, R.
    Gonzalez, J.
    Schrader, A.
    Schaefers, M.
    Boegemann, M.
    Rahbar, K.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S125 - S126
  • [26] Effect of 177Lu-PSMA-617 radioligand therapy on quality of life in patients with advanced metastatic prostate cancer
    Scheer, C.
    Juptner, M.
    Zhao, Y.
    Zuhayra, M.
    Lutzen, U.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S130 - S130
  • [27] 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
    Braeuer, Axel
    Grubert, Lena Sophie
    Roll, Wolfgang
    Schrader, Andres Jan
    Schaefers, Michael
    Boegemann, Martin
    Rahbar, Kambiz
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (10) : 1663 - 1670
  • [28] 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
    Axel Bräuer
    Lena Sophie Grubert
    Wolfgang Roll
    Andres Jan Schrader
    Michael Schäfers
    Martin Bögemann
    Kambiz Rahbar
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1663 - 1670
  • [29] Relevant tumor sink effect in prostate cancer patients receiving 177Lu-PSMA-617 radioligand therapy
    Filss, Christian
    Heinzel, Alexander
    Mueller, Berthold
    Vogg, Andreas T. J.
    Langen, Karl-Josef
    Mottaghy, Felix M.
    [J]. NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2018, 57 (01): : 19 - 25
  • [30] Patient-specific tumor dosimetry in mCRPC patients treated with 177Lu-PSMA-617
    Meyer, Catherine
    Mirando, David
    Adams, Tim
    Czernin, Johannes
    Calais, Jeremie
    Dahlbom, Magnus
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2021, 62